All Articles

The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.

Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States.

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.